Founders often feel fundraising is a marketplace with weak signals. The reality is that it's a sales process. The founder's job is to qualify leads by researching an investor's portfolio, check size, and investment thesis to find a genuine fit, rather than hoping for a match.

When capitalizing your business, select investors for their experience, not just their money. Prioritize people who have a history of successful exits. They provide a proven playbook you can model your business against and, as partners on your cap table, their strategic influence is critical to your journey.

Magic Johnson's strategy for investing in unfamiliar sectors is to analyze the cap table. The presence of reputable lead investors with a strong track record serves as a powerful signal that the opportunity has undergone rigorous due diligence, giving him the confidence to co-invest without being the expert.

When fundraising, the most critical choice isn't the VC fund's brand but the specific partner who will join the board. Sophisticated founders vet the individual's strengths, weaknesses, and working style, as that person has a more direct impact on the company than the firm's logo on a term sheet.

Investors will often be polite and say a startup is "too early." However, founders should ignore these words and instead analyze the investor's portfolio. If an investor has no history of funding pre-product companies, their feedback is irrelevant; they were never a real prospect.

Top-performing, founder-led businesses often don't want to sell control. A non-control investment strategy allows access to this exclusive deal flow, tapping into the "founder alpha" from high skin-in-the-game leaders who consistently outperform hired CEOs.

Public market investors often have only 90 days to diligence an IPO using the S-1 filing. Crossover investors who engage with companies privately for years develop a deep, historical understanding of the business and management. This long-term context provides a significant informational advantage and allows for higher conviction.

In an scientifically inscrutable sector, the percentage of a company owned by dedicated biotech funds serves as a reliable proxy for quality. A complete lack of specialist ownership is a major red flag, suggesting the company is likely marketed to uninformed investors and may have poor science.

To find startups at great prices, VCs look for "undiscovered gems" in two categories: high-potential first-time founders lacking a track record, or proven founders who are temporarily "damaged" reputationally, creating a brief window to invest at a discount.